Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Biosimilars Turkey Deals

Alvotech Links Up With Polifarma On Proposed Eylea Biosimilar

AVT06 Is Currently Undergoing Clinical Development

  • News

Executive Summary

Alvotech has signed an agreement with Polifarma to distribute its proposed aflibercept biosimilar in Turkey. The compound, AVT06, is currently in the development stage.

You may also be interested in...



Deal Watch: Novartis Acquires Gene Therapy Candidate From AvroBio

AvroBio retains rights to its other HSC gene therapy candidates. Alimera Acquires Further Commercial Rights To Eyepoint’s Uveitis Drug.

Regeneron Hopes Its High-Dose Aflibercept Will Ease Eylea Pressure

Eylea sales were below consensus for the second quarter in a row, but aflibercept 8mg approval in late June could offset the decline. Also, a late 2023 filing is planned for linvoseltamab in myeloma.

Alvotech’s Latest FDA Knockback Cuts It Fine For Humira Rival

Alvotech has received a further complete response letter from the US FDA relating to its AVT02 proposed adalimumab biosimilar rival to Humira. The latest BsUFA goal date disclosed for the product is now just a few days ahead of a potential US launch.

Table

View full table

Related Content

Generics Bulletin
Generics Bulletin
Generics Bulletin
Generics Bulletin

Topics

Related Companies

Tags:
Biosimilars Turkey Deals
Latest Headlines

Glucagon And Epinephrine Continue To Drive Growth At Amphastar

UAE’s Bioventure Is Looking For Partners To Expand

Is US FDA Preparing to Remove Some Fed Study Requirements For Generic Bioequivalence?

Medicines For Europe Highlights Industry Agenda

See All
UsernamePublicRestriction

Register

GB152714

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By